Close Menu

gene expression

NanoString Technologies this week provided investors with a mixed bag of news as it released its second quarter earnings and financial outlook for the rest of the year.

A new analysis hints that adenocarcinomas or squamous cell carcinomas may have certain overlapping expression patterns, regardless of the tissue of origin.

Researchers led by Jennifer Doudna found that the architecture of the Cas1-Cas2 integrase contributes to bacterial adaptive immunity.

Examining more than half of its genome, researchers found the parasite's success is due to stripping its genome down to essential genes.

Focusing on drugs that appeared to reverse cancer-related gene expression signatures, researchers identified candidate compounds that thwarted cancer cell lines.

A recent JAMA Oncology study highlights the power of the open-access model GenomeDx has pursued since launching its Decipher prostate cancer prognostic. 

The company has achieved even higher specificity than earlier data demonstrated, and is now building up its sales and marketing infrastructure for the planned launch of its lung cancer test.

Inflammatix hopes to market an 18-gene panel that will be able to tell from a blood sample whether a hospitalized patient has a bacterial, viral, or no infection.

Gencurix aims to achieve US FDA 510(k) clearance for its GenesWell BCT breast cancer prognostic test next year.

A comparison of single-cell RNA sequencing profiles from more than 1,000 fresh or frozen samples suggests cryopreservation does not alter general transcriptome patterns.

Pages

The Wall Street Journal looks into FamilyTreeDNA's handling of genetic genealogy searches by law enforcement.

In a point-counterpoint in the Boston Globe, researchers discuss the potential of gene editing to prevent Lyme disease, but also the pitfalls of doing so.

MIT's Technology Review reports that researchers hope to develop a CRISPR-based pain therapy.

In Science this week: atlas of malaria parasites' gene expression across their life cycles, and more.